McNeel Research Laboratory
Prostate Cancer Vaccines
Our laboratory is interested in the development of immunological treatments, and vaccines in particular, that can eradicate prostate cancer. The long-term goal of these studies is to identify in the laboratory, and test in clinical trials, vaccines that can elicit prostate cancer-destructive immune responses for the purpose of treating prostate cancer patients with minimal disease remaining after other standard therapies. This work is “translational” research, in that it uses patient-derived samples to formulate hypotheses and drive laboratory research and discovery, and then takes these laboratory findings to pre-clinical and clinical studies.
Our laboratory is interested in the development of immunological treatments, and vaccines in particular, that can eradicate prostate cancer. The long-term goal of these studies is to identify in the laboratory, and test in clinical trials, vaccines that can elicit prostate cancer-destructive immune responses for the purpose of treating prostate cancer patients with minimal disease remaining after other standard therapies. This work is “translational” research, in that it uses patient-derived samples to formulate hypotheses and drive laboratory research and discovery, and then takes these laboratory findings to pre-clinical and clinical studies.
Developing Antigen Specific DNA Vaccines as a Treatment for Prostate Cancer. Doug McNeel, MD, PhD, University of Wisconsin, Madison. Dr. McNeel is a CDMRP-funded investigator supported by the DoD Prostate Cancer Research Program (PCRP)
Developing Antigen Specific DNA Vaccines as a Treatment for Prostate Cancer. Doug McNeel, MD, PhD, University of Wisconsin, Madison. Dr. McNeel is a CDMRP-funded investigator supported by the DoD Prostate Cancer Research Program (PCRP)
